2025年EAU男性性健康与生殖健康指南更新:迟发性性腺功能减退、勃起功能障碍、早泄与佩罗尼病
该指南基于2021-2024年系统综述更新,聚焦迟发性性腺功能减退(LOH)、勃起功能障碍(ED)、早泄(PE)和佩罗尼病(PD)的诊断、治疗与随访。核心推荐强调睾酮治疗需严格掌握指征并随访,ED治疗应个体化,PE一线药物用于终身性PE,PD手术适用于影响性功能的畸形。
要点
- LOH睾酮治疗需明确指征并定期随访。
- ED治疗应基于侵入性、耐受性和疗效个体化。
- 终身性PE一线为药物治疗,获得性PE先治病因。
核心结论
- 指南为LOH、ED、PE和PD的诊断、治疗及随访提供实践推荐。
研究设计与样本
- EAU指南小组对2021-2024年Medline、EMBASE和Cochrane图书馆的新研究进行系统综述更新。
主要发现
- LOH是老年男性低循环睾酮与特定症状结合的临床状况。
- ED定义为持续无法达到和维持足够勃起以完成满意性交。
- PE采用国际性医学学会定义,需先确定亚型。
- PD基线评估应区分急性期与稳定期。
关键数值与推荐
- LOH睾酮治疗需合适指征并后续随访。
- ED治疗决策算法支持根据侵入性、耐受性、疗效和患者期望个体化治疗。
- 终身性PE药物治疗为一线,获得性PE初始目标为治疗病因。
- PD手术适用于阴茎畸形对性功能有负面影响者;合并ED者应提供阴茎假体植入。
临床怎么用
- 临床应依据指南推荐对LOH、ED、PE和PD进行规范化诊断、治疗和随访。
- ED患者应充分咨询所有可用治疗方式以制定个体化方案。
- PE患者确定亚型后讨论期望,终身性PE首选药物,获得性PE先治病因。
- PD患者基线评估区分急性与稳定期,手术指征为畸形影响性功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study is to present a summary of the updated 2025 European Association of Urology (EAU) guidelines on sexual and reproductive health (SRH), focusing on hypogonadism, erectile dysfunction (ED), premature ejaculation (PE), and Peyronie's disease (PD), providing practical recommendations on the clinical workup, with a focus on diagnosis, treatment, and follow-up. EVIDENCE ACQUISITION: The panel conducted an updated systematic review of new research published in 2021-2024 in Medline, EMBASE, and Cochrane Libraries. The guidelines' recommendations focused on key clinical decisions that would impact patient care most. Each recommendation's strength was evaluated based on three factors: the trade-offs between benefits and drawbacks of different treatment approaches, the quality and reliability of the available evidence, and the diverse preferences and values of patients. KEY FINDINGS: Along with a detailed basic and advanced diagnostic approach for every condition, key recommendations emphasise the importance of appropriate indications and subsequent follow-up for testosterone therapy in patients with late-onset hypogonadism (LOH), a clinical condition in the ageing male combining low levels of circulating testosterone and specific symptoms associated with impaired hormone production and/or action. The decision-making algorithm for treating ED-defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance-aims to support personalised treatment tailored to individual patients, according to the invasiveness, tolerability, and effectiveness of the different therapeutic options and patients' expectations. Hence, patients should be fully counselled with respect to all available treatment modalities. The EAU guidelines adopted the definition of PE, which has been developed by the International Society for Sexual Medicine. After the subtype of PE has been defined, patient's expectations should be discussed thoroughly, and pharmacotherapy must be considered as the first-line treatment for patients with lifelong PE, whereas treating the underlying cause must be the initial goal for patients with acquired PE. An accurate baseline assessment of patients with PD should differentiate between acute and stable phases of the disorder. Surgical treatment for PD should be offered to patients having a penile deformity with a negative impact on sexual function: patients with concomitant ED should be offered penile prosthesis implantation. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2025 EAU SRH guidelines offers valuable insights into the diagnosis, treatment, and follow-up of LOH, ED, PE, and PD.
引用
- Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie's Disease. Eur Urol. 2025. PMID: 40340108. doi:10.1016/j.eururo.2025.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。